Presentations by Program

Search by Program

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam (ETX2514) against Pathogenic Burkholderia Species

Miller AA, O'Donnell JP, Lane DJ, Panchal RG and Mueller JP (IDWeek 2019)

Resistance to Sulbactam-Durlobactam in Clinical Isolates of Acinetobacter baumannii is Rare and Maps to PBP3

Moussa S, Shapiro AB, McLeod SM and Miller AA (Acinetobacter 2019)

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β-lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

O'Donnell J (Microbe 2019)

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Huband M, Edah Y, Tommasi R and Miller A (Microbe 2019)

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

Onufrak NJ, Rubino CM, Ambrose PG, Isaacs R, Srinivasan S and O'Donnell J (ECCMID 2019)

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Global Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M, Tommasi R and Miller A (ECCMID 2019)

The Susceptibility of Sulbactam/ETX2514 and Comparators to Global Isolates of Acinetobacter baumannii

Seifert H, Stefanik, D, Muller C, Higgins P, Kresken M and Miller A (ECCMID 2019)

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Srinivasan S (ECCMID 2019))

ETX2514SUL (Sulbactam/ETX2514) for The Treatment of Acinetobacter baumannii Infection

Isaacs R (IDWeek 2018)

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Clinical Isolates of Acinetobacter baumannii, Including Extensively Drug-Resistant (XDR) Isolates Expressing OXA-237

Sarah McLeod, ASM Microbe 2018